<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707768</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0039</org_study_id>
    <nct_id>NCT04707768</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects</brief_title>
  <official_title>A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to demonstrate the efficacy and safety of vadadustat&#xD;
      administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating&#xD;
      agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following randomization, there will be 2 periods during the study:&#xD;
&#xD;
        -  Conversion and Maintenance Period (Weeks 0 to 52): conversion to vadadustat TIW or to&#xD;
           remain on Mircera® (Weeks 0 to 20). There will be a primary efficacy evaluation period&#xD;
           (Weeks 20 to 26) and a secondary efficacy evaluation period (Weeks 46 to 52).&#xD;
&#xD;
        -  Safety Follow-up Period (Early Termination [ET] and Follow-Up): post-treatment safety&#xD;
           follow-up visit (ET/End of Treatment [EOT] +4 weeks) either in person or via telephone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in hemoglobin (Hb) between Baseline (average pretreatment Hb) and the primary evaluation period (average Hb from Weeks 20 to 26, inclusive)</measure>
    <time_frame>Baseline; Weeks 20-26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent non-serious adverse events and treatment-emergent serious adverse events</measure>
    <time_frame>up to Week 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Hb between Baseline (average pretreatment Hb) and the secondary evaluation period (average Hb from Weeks 46 to 52, inclusive)</measure>
    <time_frame>Baseline; Weeks 46-52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Anemia Associated With Chronic Kidney Disease (CKD)</condition>
  <arm_group>
    <arm_group_label>Vadadustat low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously receiving Mircera® will receive a low dose of vadadustat for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vadadustat high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously receiving Mircera® will receive a high dose of vadadustat for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircera®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will continue to receive Mircera® for up to 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vadadustat</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>Vadadustat high dose</arm_group_label>
    <arm_group_label>Vadadustat low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mircera®</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Mircera®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Receiving chronic, outpatient in-center hemodialysis three times weekly (TIW) for&#xD;
             end-stage kidney disease for at least 12 weeks prior to Screening Visit 1 (SV1)&#xD;
&#xD;
          -  Currently maintained on Mircera® with at least 2 doses received within 8 weeks prior&#xD;
             to Screening Visit 2 (SV2)&#xD;
&#xD;
          -  Mean Screening hemoglobin (Hb) between 8.5 and 11.0 grams per deciliter (g/dL)&#xD;
             (inclusive), as determined by the average of 2 Hb values measured by the central&#xD;
             laboratory at least 4 days apart between SV1 and SV2&#xD;
&#xD;
          -  Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT)&#xD;
             ≥20% during Screening&#xD;
&#xD;
          -  Folate and vitamin B12 measurements ≥ lower limit of normal during Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia due to a cause other than chronic kidney disease (CKD) (e.g., sickle cell&#xD;
             disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy,&#xD;
             myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia)&#xD;
&#xD;
          -  Clinically meaningful bleeding event in opinion of Investigator within 8 weeks prior&#xD;
             to Baseline&#xD;
&#xD;
          -  Red blood cell (RBC) transfusion within 8 weeks prior to Baseline&#xD;
&#xD;
          -  Having received any doses of darbepoetin alfa (Aranesp®) within 4 weeks prior to&#xD;
             Baseline&#xD;
&#xD;
          -  Having received any doses of epoetin alfa (Epogen®) within 1 week prior to Baseline&#xD;
&#xD;
          -  Anticipated to discontinue hemodialysis during the study&#xD;
&#xD;
          -  Judged by the Investigator that the participant is likely to need rescue therapy&#xD;
             (erythropoiesis-stimulating agent [ESA] administration or RBC transfusion) immediately&#xD;
             after enrollment in the study&#xD;
&#xD;
          -  History of chronic liver disease (e.g., chronic infectious hepatitis, chronic&#xD;
             autoimmune liver disease, cirrhosis or fibrosis of the liver)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT),&#xD;
             alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total&#xD;
             bilirubin &gt;2 x upper limit of normal (ULN) during Screening. Participants with a&#xD;
             history of Gilbert's syndrome are not excluded.&#xD;
&#xD;
          -  Current uncontrolled hypertension as determined by the Investigator that would&#xD;
             contraindicate the use of an ESA&#xD;
&#xD;
          -  Acute coronary syndrome (hospitalization for unstable angina or myocardial&#xD;
             infarction), surgical or percutaneous intervention for coronary, cerebrovascular or&#xD;
             peripheral artery disease (aortic or lower extremity), surgical or percutaneous&#xD;
             valvular replacement or repair, sustained ventricular tachycardia, hospitalization for&#xD;
             heart failure (HF) or New York Heart Association Class IV HF, or stroke within 12&#xD;
             weeks prior to or during Screening&#xD;
&#xD;
          -  History of new, active or recurrent malignancy within 2 years prior to and during&#xD;
             Screening or currently receiving treatment or suppressive therapy for cancer.&#xD;
             Participants with treated basal cell carcinoma of skin, curatively resected squamous&#xD;
             cell carcinoma of skin, or treated cervical carcinoma in situ are not excluded.&#xD;
&#xD;
          -  History of deep vein thrombosis or pulmonary embolism within 12 weeks prior to or&#xD;
             during Screening&#xD;
&#xD;
          -  History of hemosiderosis or hemochromatosis&#xD;
&#xD;
          -  History of prior organ transplantation (participants with a history of failed kidney&#xD;
             transplant or corneal transplants are not excluded)&#xD;
&#xD;
          -  Scheduled organ transplant from a living donor and participants on the kidney&#xD;
             transplant wait-list who are expected to receive a transplant within 6 months&#xD;
&#xD;
          -  History of a prior hematopoietic stem cell or bone marrow transplant (stem cell&#xD;
             therapy for knee arthritis is not excluded)&#xD;
&#xD;
          -  Known hypersensitivity to vadadustat, Mircera®, or any of their excipients&#xD;
&#xD;
          -  Use of an investigational medication or participation in an investigational study&#xD;
             within 30 days or 5 half-lives of the investigational medication (whichever is&#xD;
             longer), prior to Screening (participants may participate in another concurrent study&#xD;
             only if that study is a non-interventional, observational investigation)&#xD;
&#xD;
          -  Current exposure to any hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor&#xD;
             or prior exposure to vadadustat&#xD;
&#xD;
          -  Participants with bilateral native nephrectomy&#xD;
&#xD;
          -  Noncompliance with dialysis session attendance defined as missing more than 1 dialysis&#xD;
             session within 8 weeks prior to Baseline&#xD;
&#xD;
          -  Active Severe Acute Respiratory Syndrome-Related Coronavirus (SARS CoV-2) during&#xD;
             Screening&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding during Screening or are planning to become&#xD;
             pregnant and breastfeeding during the study period, and for 30 days after the final&#xD;
             study drug administration&#xD;
&#xD;
          -  Women of childbearing potential who are unable or unwilling to use 2 acceptable&#xD;
             methods of contraception starting at Screening, throughout the study period and for 45&#xD;
             days after the final study drug administration. Acceptable methods of contraception&#xD;
             include (a.) established use of oral, injected, or implanted hormonal methods of&#xD;
             contraception; (b.) placement of an intrauterine device or intrauterine system; (c.)&#xD;
             barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault&#xD;
             caps) with spermicidal foam/gel/film/cream/suppository.&#xD;
&#xD;
          -  Female participants of childbearing potential who plan to donate ova during the study,&#xD;
             and for 30 days after the last dose of study drug&#xD;
&#xD;
          -  Non-vasectomized male participants who are unable or unwilling to use an acceptable&#xD;
             method of contraception from time of first dose of study drug until 30 days after the&#xD;
             last dose of the study drug&#xD;
&#xD;
          -  Male participants who plan to donate sperm during the study and for at least 30 days&#xD;
             after the last dose of study drug&#xD;
&#xD;
          -  Any other reason, which in the opinion of the Investigator, would make the participant&#xD;
             not suitable for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Akebia Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akebia Therapeutics</last_name>
    <phone>617-844-6128</phone>
    <email>trials@akebia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porterville</city>
        <state>California</state>
        <zip>93257</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hockessin</city>
        <state>Delaware</state>
        <zip>19707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site#1</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site#2</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70884</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brookhaven</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mansfield</city>
        <state>Texas</state>
        <zip>76063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission</city>
        <state>Texas</state>
        <zip>78572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22192</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vadadustat</keyword>
  <keyword>Erythropoiesis-stimulating agent (ESA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

